Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries

Accepted/In Press date: 8 December 2020

e-pub ahead of print date: 24 February 2021

Published date: 24 February 2021

Additional Information: Funding Information: This work was conducted using the UK Biobank Resource (application number 25331) and publicly available data from the International Glaucoma Genetics Consortium. This work was also supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (#1107098; 1116360, 1116495, 1023911), the Ophthalmic Research Institute of Australia, the BrightFocus Foundation, UK and Eire Glaucoma Society and Charitable Funds from Royal Liverpool University Hospital, and International Glaucoma Association-Royal College of Ophthalmologists. P.G. is supported by a NHMRC Investigator Grant (#1173390). S.M., J.E.C., K.P.B., and A.W.H. are supported by NHMRC Fellowships. A.P.K. was funded by a Moorfields Eye Charity Career Development Fellowship, a UK Research and Innovation Future Leaders Fellowship and an Alcon Research Institute Young Investigator Award. The EPIC-Norfolk study has received funding from the Medical Research Council (MR/N003284/1, MC-UU_12015/1, and MC_PC_13048) and Cancer Research UK (C864/A14136). The NEIGHBORHOOD consortium is supported by NIH grants P30 EY014104, R01 EY015473, and R01 EY022305. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/ 31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). This work was also supported by the National Eye Institute/National Institutes of Health [R01EY018246, and support from the National Institutes of Health Center for Inherited Disease Research to T.L.Y.]; a University of Wisconsin Centennial Scholars Award [to T.L.Y.]; and an unrestricted grant from Research to Prevent Blindness, Inc. to the UW-Madison Department of Ophthalmology and Visual Sciences [to T.L.Y.]. Additional acknowledgments are supplied in the Supplementary Information file. Funding Information: X.W. and A.A. are employed by and hold stock or stock options in 23andMe, Inc. J.W. is a consultant for Allergan, Editas, Maze, Regenxbio and has received sponsored research support from Aerpio Pharmaceuticals Inc. L.P. is a consultant for Eyenovia, Bausch + Lomb, Verily, and Nicox. T.L.Y. serves as a consultant to Aerpio Pharmaceuticals, Inc. A.P.K. is a consultant to Aerie, Allergan, Google Health, Novartis, Reichert, Santen and Thea. All remaining authors declare no competing interests. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Local EPrints ID: 448453

URI: http://eprints.soton.ac.uk/id/eprint/448453

DOI: doi:10.1038/s41467-020-20851-4

ISSN: 2041-1723

PURE UUID: 1dd8188f-95c9-401a-a78f-b58cbe787fa8

ORCID for Angela J. Cree: orcid.org/0000-0002-1987-8900

ORCID for Roxana Carare: orcid.org/0000-0001-6458-3776

ORCID for Sarah Ennis: orcid.org/0000-0003-2648-0869

ORCID for Jane Gibson: orcid.org/0000-0002-0973-8285

ORCID for Andrew J. Lotery: orcid.org/0000-0001-5541-4305

ORCID for Jay Self: orcid.org/0000-0002-1030-9963

ORCID for Irene Stratton: orcid.org/0000-0003-1172-7865

ORCID for Andrew J. Lotery: orcid.org/0000-0001-5541-4305

Date deposited: 22 Apr 2021 16:46

Last modified: 15 Oct 2024 02:01